Apellis Pharmaceuticals (apls 3.5 09/15/26)
13F holders, Q1 2024 (March 31)2holders
$1.64avg. 13F price*
At the end of Q1 2024, 2 institutions reported holding Apellis Pharmaceuticals (apls 3.5 09/15/26) in their 13F filings. The largest holders were Opti Capital Management, LP ($6.2M) and Lord, Abbett & Co. LLC ($1.9M).
- Company
- Apellis Pharmaceuticals (apls 3.5 09/15/26)
- CUSIP
- 03753UAB2
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $8.0M |
| Exits | 0 | $0 |
Ownership 2 holders
| Opti Capital Management, LP | 0.47% | New | 3,750,000 | $6.2M |
| Lord, Abbett & Co. LLC | 0.01% | New | 1,135,000 | $1.9M |
"% of holder's portfolio" is APELLIS PHARMACEUTICALS (APLS 3.5 09/15/26)'s weight in each manager's 13F, not the share of Apellis Pharmaceuticals (apls 3.5 09/15/26) the manager owns.